Fear of ‘Humanized’ Pigs Blocks Advances in Organ Transplantation

Research into the potential of growing human organs inside pigs has faced significant regulatory hurdles in the United States, primarily due to concerns over the ethical implications of “humanized” animals. While advancements continue in laboratories, particularly with gene-edited pig kidneys, federally funded efforts to cultivate fully human organs within pigs remain stalled.

The issue traces back to a decision made by the National Institutes of Health (NIH) in 2015, which halted funding for studies involving human stem cells in animal embryos. At that time, the NIH expressed concerns that human cells could migrate into an animal’s brain, potentially altering its cognitive functions. This fear of creating pigs that might exhibit human-like traits has led to a regulatory freeze on certain types of research in this area.

In a notable development, surgeons in New York successfully transplanted a genetically modified pig kidney into a patient in October 2025. This procedure marked the first clinical trial of its kind, utilizing a kidney from a pig engineered to minimize immune rejection, rather than one produced with human cells. Currently, six patients are participating in this trial, which aims to determine the safety and functionality of gene-edited pig organs in humans.

The drive behind xenotransplantation—transplanting organs from one species to another—stems from a critical need. More than 100,000 people in the United States are on organ transplant waiting lists, and thousands die each year while waiting for suitable donor organs. Researchers have explored cross-species solutions for decades, dating back to the 1960s with baboon hearts, to today’s pig models refined through advanced gene-editing techniques like CRISPR.

Despite the promise of these innovations, the immune system presents a major challenge. Recipients of pig organs typically require lifelong immunosuppressant medications to prevent organ rejection. For instance, a patient in New Hampshire who underwent a pig kidney transplant in January 2025 had the organ removed nine months later due to declining function, underscoring the ongoing risks involved.

Interest in developing organs using a patient’s own cells within animals intensified prior to the NIH’s funding pause. This approach proposed an elegant solution: disable the ability of an animal embryo to grow a specific organ, then introduce human stem cells to fill the void. Theoretically, this method could yield a patient-matched organ with significantly reduced rejection risks. Researchers had previously demonstrated the feasibility of this concept by successfully growing a mouse pancreas within a rat.

Ethical considerations, rather than technical limitations, led to the cessation of this research. Regulators focused on the potential for human cells to influence an animal’s brain, which some ethicists have deemed an arbitrary distinction. Pigs already possess human genes to facilitate organ transplants, yet they are not perceived as partially human. In reality, regulatory protections tend to follow species lines rather than cellular composition.

As a result, a peculiar compromise has emerged within the field of medicine. While the transplantation of pig organs into humans has gained acceptance, the pursuit of cultivating human organs within pigs remains prohibited, even when the goal is to save lives. The ongoing debate surrounding this issue reflects broader ethical concerns about the intersection of human and animal biology, and it underscores the challenges that lie ahead in addressing critical organ shortages.